



In silico analysis of the MRP1 Protein implicated in Neuroblastoma

Sangeeta Sharma

Department of Bioinformatics, D.A.V. College, Sector-10, Chandigarh

Abstract: MRP1 is a uni-directional efflux transporter that confers multidrug resistance and mediates the efflux of both endobiotic and xenobiotic organic anions. MRP1 transports many therapeutic and physiological substrates. It has a key role in the onset of drug resistance in several cancers for example lung, breast, prostate, and childhood neuroblastoma. In the present work, the wild type and mutant protein sequence of MRP1 protein were analysed using an *in silico* approach for studying the functional role of the MRP1 protein in the normal and diseased condition. The variation in the mutant protein was analysed at the structural level to decipher the mode of the disease progression.

Keywords: Multidrug resistance, Neuroblastoma, *in silico*, MRP1.

INTRODUCTION

Multidrug resistance protein 1 (MRP1/ABCC1) is a transmembrane protein of the ATP-binding cassette superfamily as exemplified in the Pfam database (1,2). When the expression of the gene is exceptionally high in tumour cells, MRP1 shows resistance to antineoplastic drugs and other xenobiotics (3, 5). MRP1 facilitates the ATP-dependent efflux of organic anions derived from endogenous metabolites and exogenous xenobiotics which are complexed with the tripeptide molecule Glutathione (4, 6, 7).

MRP1 is ubiquitously expressed in humans. The mRNA is highly expressed in testis, cardiomyocytes, placenta, prostate, lung, thymus, and kidney, with lower expression is seen in small intestine, colon, brain, and mononuclear cells (11).

MRP1 has a molecular weight of 190-kDa. It has a core structure of three membrane-spanning domains (MSDs) and two nucleotide-binding domains (NBDs). The MSDs contain five to six transmembrane segments which forms a pore in the lipid through which solutes are extruded out of the cell (8, 9).




Fig:1 Topology and domain structure of MRP1

The two NBDs of MRP1 coordinate to form a sandwich dimer that comprises two composite nucleotide binding sites, which bind and hydrolyse ATP to provide the energy necessary for the transport process (Fig.1)

The Transmembrane α -helices of the core membrane spanning domains forms the channel for the translocation of substrates. They lie close to the Nucleotide Binding Domains by means of the cytoplasmic loops that connect the helical region (11). The loops facilitate the juxtaposition of the ATPase activity at the nucleotide binding sites for the process of transport of substances.

MRP1 has a significant role to play in the inflammatory responses (12).

MULTIDRUG TRANSPORTER PROTEIN1 IN CANCER: -

Drug resistance is a major challenge to cancer treatment and leads to poor diagnosis in the people carrying the mutation. MRP1 plays a great role in the onset of the drug resistance in Neuroblastoma (15). Neuroblastoma leads to solid tumour outside the cranium in children. It is usually seen in the cells of neural crest origin. High copy number of the MycN oncogene is remarkably a significant manifestation clinically for neuroblastoma. The amplification of MycN is seen in 25% of primary neuroblastomas and thereby leads to rapid tumour progression and can be manifested clinically.

MycN is related to Myc family that codes for transcription factors. It is involved in the growth and differentiation of neuroblastoma cells. Studies on the MRP1 promoter has suggested that MycN keeps a check on the expression of MRP1 gene through interaction with a putative E-box element and other cis-acting elements in the MRP1 promoter region. Neuroblastoma cells over expressing MycN have enhanced levels of Multidrug Transporter protein and eventually become intolerant to well-characterized MRP1 substrate drugs (5, 15).

MRP1 is implicated in cell differentiation and cell death in this disease (10,13).




Fig.1.1. MRP1 regulation by MycN and its role in drug resistance.

METHODOLOGY

Sequence retrieval: The wild type (NP_004987) and the mutant (NP_009487.2) MRP1 protein in *Homo sapiens* was extracted from the protein sequence database at NCBI. **Fig.2 and 3.**

CDD: Conserved domains in wild type and diseased MRP1 protein were studied by Conserved Domain Database (www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). **Fig 4, 5.**

Phyre2: Tertiary structure of normal and mutant MRP1 was compared to analyse the impact of mutation on the 3D structure of protein. **Fig 6 and 7**

RESULTS AND DISCUSSIONS

The MRP1 protein sequence of *Homo sapiens* was retrieved from NCBI protein database. The wild type protein has a length of 1531 residues while the protein showing variation has 1472 residues. **Fig 2 and 3.**



NCBI Resources How To Sign in to NCBI

Protein Protein Advanced Search Help

NCBI is phasing out sequence GI numbers in September 2016. Please use accession.version! [Read more...](#)

GenPept+ Send to: Change region shown


multidrug resistance-associated protein 1 [Homo sapiens]

NCBI Reference Sequence: NP_004987.2
[Identical Proteins](#) [FASTA](#) [Graphics](#)

Go to:

LOCUS NP_004987 1531 aa linear PRI 15-NOV-2015
 DEFINITION multidrug resistance-associated protein 1 [Homo sapiens].
 ACCESSION NP_004987
 VERSION NP_004987.2 GI:134142337
 DBSOURCE REFSEQ: accession [NM_004996.3](#)
 KEYWORDS RefSeq.
 SOURCE Homo sapiens (human)
 ORGANISM [Homo sapiens](#)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
 Catarrhini; Hominidae; Homo.
 REFERENCE 1 (residues 1 to 1531)
 AUTHORS Song Y, Zhou X, Bai W and Ma X.
 TITLE FBW7 increases drug sensitivity to cisplatin in human
 nasopharyngeal carcinoma by downregulating the expression of
 multidrug resistance-associated protein
 JOURNAL Tumour Biol. 36 (6), 4197-4202 (2015)
 PUBMED 25586348
 REMARK GeneRIF: The level of FBW7 expression in CNE2 cells was correlated
 with CDDP chemosensitivity. siRNA-mediated upregulation of FBW7
 expression downregulated the expression of MRP, significantly
 increasing drug sensitivity in CNE2 cells.
 REFERENCE 2 (residues 1 to 1531)
 AUTHORS Hong Y, Lai YT, Chan GC and Sun H.
 TITLE Glutathione and multidrug resistance protein transporter mediate a
 self-propelled disposal of bismuth in human cells

[Protein 3D Structure](#)



Nucleotide-free Crystal Structure Of Nucleotide-binding Domain 1 From PDB: 4C3Z
 Source: Homo sapiens
 Method: X-Ray Diffraction
 Resolution: 2.1 Å
 See all 2 structures...

[Articles about the ABCC1 gene](#)

Glutathione and multidrug resistance protein transporter mei [Proc Natl Acad Sci U S A. 2015]
 RNAi-based knockdown of multidrug resistance-ass [Asian Pac J Cancer Prev. 2014]
 Emodin augments cisplatin cytotoxicity in platinum-resistant ovaria [Biomed Res Int. 2014]

Site /note="propagated from UniProtKB/Swiss-Prot (P33527.3)"
 1090..1110
 /site_type="transmembrane region"
 /experiment="experimental evidence, no additional details recorded"
 Site /note="propagated from UniProtKB/Swiss-Prot (P33527.3)"
 1112..1132
 /site_type="transmembrane region"
 /experiment="experimental evidence, no additional details recorded"
 Site /note="propagated from UniProtKB/Swiss-Prot (P33527.3)"
 1204..1224
 /site_type="transmembrane region"
 /experiment="experimental evidence, no additional details recorded"
 Site /note="propagated from UniProtKB/Swiss-Prot (P33527.3)"
 1227..1247
 /site_type="transmembrane region"
 /experiment="experimental evidence, no additional details recorded"
 Region /note="propagated from UniProtKB/Swiss-Prot (P33527.3)"
 1291..1511
 /region_name="ABCC_MRP_domain2"
 /note="ATP-binding cassette domain 2 of multidrug resistance-associated protein; cd083244"
 /db_xref="CDD:213211"
 CDS 1..1531
 /gene="ABCC1"
 /gene_synonym="ABC29; ABCC; GS-X; MRP; NRP1"
 /coded_by="NM_004996.3:176..4771"
 /db_xref="CCDS:CCDS42122.1"
 /db_xref="GeneID:4363"
 /db_xref="HGNC:HGNC:51"
 /db_xref="MIM:158343"

ORIGIN
 1 malingfsaad gsdplwdmrv tmtstnpdft kcfqntvlwv vpcfylwacf pfyflylserh
 61 drgyiqmtpi nktktalgfl lwlvwadlf ysfuensngi flapvflvsp tllgitmla
 121 tflilqlernk gvqssgimlt fwlvvalcal ailrskimta lkedaqvdlf rditfyvyfs
 181 lllliqlvlsc fsdrspifse tihdnpocpe ssaaflsruit fwitglivr gyrgplegad
 241 lwlknkedts eqvvpvlvkn wkkecaktrk qvkvvyssk dpaqpkessk vdaneeeval
 301 ivkspqkemin pslfkvllykt fgpyflmsff fkaihdlemf sgpqilklli kfndtkapd
 361 wqgyfytull fvtaclqtly lhqyfhicfv sgmriktavi gavyrkalvi tnsaekastv
 421 geivnlmsvd sqrfndlaty inniwsap1q vilalyllwl nlgspsvlagv avmvlmvpm
 481 amamkktky qvahmkskdn riklmeiln gikvklkyaw elafkdkvla inqeelkvk
 541 ksalyavugt fawvctpf1v alctfavyvt idennildaq tafvslalfn ilrfplnilp
 601 mvissivqas vslkrlnrfl sheelepdsi erpvrkdggg tnsitvrnat fwuansdppt
 661 lngitfsipe galvavvgqv gcgkssllsa llasmdkveg hvaikgsavv vppqawiqnd
 721 slrenilfgc qleepyyrvz iqacallpd1 eilpsgdnte igekgvnlsg gqkqvslar
 781 avysnadlyl fddplsaavda hvqkhi fenv igpkgnlknk trilvthms ylpqvduviiv
 841 msqgkiseng syqellandg afaeflnty steqeadaee ngvtgvsqpg keakqmenng
 901 lytdsagkql qrlssossy sgdisirhhns taelqkaeak keetnkimes dkaqtgqvkl
 961 svywdymkai glfisflisf lfmcnhvsal asnywls1wt ddpivngtqe htkvrlsvyg
 1021 algisoglav fgysnavsig gilasrc1hw dl1hsilnsp nsffertpsg nlvnrfskel
 1081 dtvdsvmpv ikmfnsg1fn vlgacivill atpiaaiip plgliyffvq rfyvasarql
 1141 krlesvmsp vyshfnetll gvsvirafee qerfihqsd1 kvdenqkayy psivanrwla
 1201 vrlecvgnci vlfaalfavi srhslsaglv glsvsylvq ttylnvlvm smemetniva
 1261 verlkeyset ekeapwaiqe tappsswpqv grvefnnycl ryredldful rhinvtingg
 1321 ekvgivgrtg agksslt1gl frinesaage iisdginsak iglhd1rfki tiipqdpvlf
 1381 sr1rmndp fsqysdeeww tslelahlkd fvsalpdkld hecaeggenl svgrq1lvc1
 1441 sr1lnktki lvldestaav dletddliqs tirtqfedct vltishrlnt imdytrvvl
 1501 dkgeiqeyga psd1lqrg1 fyzsmkdg1 v

Fig 2: The wild type MRP1 (Homo sapiens) protein.

Protein

ⓘ NCBI is phasing out sequence GI numbers in September 2016. Please use accession.version! [Read more...](#)

GenPept ▾

multidrug resistance-associated protein 1 isoform 2 [Homo sapiens]

NCBI Reference Sequence: NP_063915.2

⚠ Record removed. NM_019862.2: This RefSeq was permanently suppressed because currently there is no full-length support for the transcript and the protein.

[Identical Proteins](#) [FASTA](#) [Graphics](#)

Go to:

LOCUS	NP_063915	1472 aa	linear	PRI 01-APR-2012
DEFINITION	multidrug resistance-associated protein 1 isoform 2 [Homo sapiens].			
ACCESSION	NP_063915			
VERSION	NP_063915.2 GI:134142340			
DBSOURCE	REFSEQ: accession NM_019862.2			
KEYWORDS	RefSeq.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.			
REFERENCE	1 (residues 1 to 1472)			
AUTHORS	Chen,M., Xue,X., Wang,F., An,Y., Tang,D., Xu,Y., Wang,H., Yuan,Z., Gao,W., Wei,J., Zhang,J. and Miao,Y.			
TITLE	Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer			
JOURNAL	Oncol. Rep. 27 (1), 265-269 (2012)			
PUBMED	21956451			
REMARK	GeneRIF: ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP expression correlated with pancreatic cancer tumorigenesis and drug resistance in a mechanism that is independent of promoter methylation			
REFERENCE	2 (residues 1 to 1472)			
AUTHORS	Cho,S., Lu,M., He,X., Ee,P.L., Bhat,U., Schneider,E., Miele,L. and Beck,W.T.			
TITLE	Mdr1 regulates the suppression of the multidrug resistance gene			

CDS

```

/product="multidrug resistance-associated protein 1
isoform 2"
/note="multidrug resistance-associated protein 1;
leukotriene C(4) transporter; LTC4 transporter;
ATP-binding cassette transporter variant ABCC1delta-ex13;
ATP-binding cassette transporter variant ABCC1delta-ex13&14;
ATP-binding cassette transporter variant
ABCC1delta-ex25&26"
/calculated_mol_wt=164840
1..1472
/gene="ABCC1"
/gene_synonym="ABC29; ABCC; GS-X; MRP; MRP1"
/coded_by="NM_019862.2:176..4594"
/note="isoform 2 is encoded by transcript variant 2"
/db_xref="CCDS:CCDS45427.1"
/db_xref="GeneID:4363"
/db_xref="HGNC:HGNC:51"
/db_xref="HPRD:01153"
/db_xref="MIM:158343"

```

RIGIN

```

1 malrgfcsad gsdplwdwnv twntsnpdft kcfqntvlvw vpcfylwacf pfyflylsrh
61 drgyiqmtp1 nktktalglf lwivcwadlf ysfwersngi flapvflvsp tllgitmla
121 tfliaqlerrk gvqssgimlt fwlvalvcal ailrskimta lkedaqvd1f rditfyvyfs
181 llliaqlvlsc fsdrsp1fse tihdnpncpe ssasflsrit fwwitglivr gyrrp1egsd
241 lwslnkedts eqvvpvlvkn wkkecaktrk qpvkvyssk dpaqpkessk vdaneeeval
301 ivkspqkewn ps1fkvlykt fgpyflmsff fkaihdlmmf sgpqilklli kfvdntkapd
361 wqgyfytv11 fvtac1qtlv lhqyfhicfv sgmriktavi gavyrkalvi tnsarksstv
421 geivnlmsvd aqrfmdlaty inmiwsaplq vilalyl1w1 nlgpsvlagv avmvlmpvvn
481 avmamktkty qvahmkskdn riklmeiln gikvlklyaw elaFkdKv1a irqeelkv1k
541 ksays1avgt ftwvctpf1v alctfavyvt idennildaq tafvslalfn ilrfplnilp
601 mvissivqas vs1krlrif1 sheelepdsi errpvkdggg tnsitvrnat ftwarsdppt
661 lngitfsipe galvavvgqv cgc1kss1l1sa llaemdkveg hvaikgvn1s ggqkqrvs1a
721 ravysnadiy lfd1dpl1savd ahvgkhifen vigp1k1m1kn ktrilvth1sm sylp1qvdv1i
781 vms1gk1sem gsyqellard gafaeflrty asteqe1qdae engvtgvsgp gkeakq1meng
841 mlvt1ds1agk1q l1rq1l1ss1ss1s ysgdisrhhn staelqkaea kkeetw1k1me adkaqtg1qv1k
901 lsvywdymka ig1lfis1fl1si flfmcnhvsa lasnyw1s1lw tddpivngtq ehtkvr1lsvy
961 galgis1qgia vfgysmavsi ggilasrclh vdl1hs1l1rs pmsffertps gnlvnrfske
1021 ldtvds1mipe vikmfms1s1f nvigacivil latpiaa1i1i pplgl1iy1ffv qrfyvassr1q
1081 lkr1lesv1rs pyyshfnet1 lgvsvirafe eqerfi1h1qd lkvdnqkay ypsivanr1w1l
1141 avr1lecvgnc iv1faal1fav isrhs1s1agl vglsvs1s1lq vtt1yn1w1lv1r mssem1et1n1v
1201 aver1keyse tekeapw1q1 etappssw1p1q vgrvefrnyc lryred1dfv lrhin1v1ting
1261 gekvgiv1g1rt gagkss1t1lg lfrinesaeg eiiidg1nia kig1hd1lrfk itiip1q1d1p1v
1321 fsgs1lrm1ld pfsqys1deev wts1el1alahk dfvsal1pd1k1 dhcaeggen lsvgqr1q1lvc
1381 lar1al1rktk ilv1deataa vdl1etdd1liq stirtq1fedc tv1tiahr1ln timdytr1v1v
1441 ldkgeiqe1yg apsdl1l1qrg lfysmak1dag lv

```

Fig 3: The mutant MRP1 (*Homo sapiens*) protein.

2015, RHIMRJ, All Rights Reserved

Page 4 of 7

ISSN: 2349-7637 (Online)

The CDD analysis of wild type MRP1 revealed that it has transmembrane regions and two ATP binding domains. The two domains consist of nucleotide binding sites which are involved in hydrolysing ATP to provide the energy for the transport mechanism. In the domain1 the residues walker B motif, A loop, D loop, H loop contribute to ATP binding and hydrolysis. The Q loop significantly interacts with metal cofactor to facilitate ATP binding and other residues of the loop lead to conformational variations in nucleotide binding domains (NBD) and transmembrane domains that are involved in ATP dependent transport of solute molecules.

CDD analysis of mutant MRP1 revealed that the Q loop is missing at domain1. Variations in the MRP1 protein results in loss of activity of the wild type MRP1 protein. The mutation at the Q loop region of NBD1 in mutant MRP1 results in deletion of Q loop that differs it from normal protein and leads to the formation of truncated protein. Loss of MRP1 protein function or its over expression in tissues might lead to the decrease in the efficacy of drug administration in Neuroblastoma.




Fig. 4 Conserved domains in wild type MRP1 *Homo sapiens* Protein.




Fig. 5 Conserved domains in mutant MRP1 *Homo sapiens* Protein.

The missing hydrophilic amino acid Glutamine in the Q-loops of MRP1 have a crucial role to play role in Mg·ATP binding, and in inter-domain communications between the NBDs and TMDs.




Fig. 6 Tertiary Structure Prediction of MRP1 (Wild type) by Phyre2 and 3D Visualisation by JSmol




Fig. 7 Tertiary Structure Prediction of MRP1 (mutant) by Phyre2 and 3D Visualisation by JSmol

CONCLUSION

MRP1 has a critical impact on the drug efficacy of different cancers and majorly leads to inflammatory responses.

Domain comparison of the wild type and mutant protein revealed that in ATP binding domain 1 the Q loop interacts with metal cofactor to participate in ATP binding and other residues to transmit the conformational changes between NBDs and integral domains, in ATP dependent solute transport. Therefore, the mutation at the Q loop region of NBD1 in the mutant MRP1 results in deletion of Q loop that remarkably differs in the normal protein and hence the formation of a shorter protein. Loss of MRP1 protein function or its unusually abnormal expression in tissues might be the causative reason for drug resistance behaviour in Neuroblastoma. The missing glutamine residues in the Q-loops of the protein have a significant role to play role in Mg·ATP binding, and in inter-domain communications amongst the Nucleotide binding domains and Transmembrane domains.

REFERENCES

- Higgins C. F. ABC transporters: from microorganisms to man. *Annu. Rev. Cell Biol.* **1992**, 8, 67–113.
- Slot A. J., Molinski S. V., Cole S. P. C. Mammalian Multidrug resistance proteins (MRPs). *Essays Biochem.* **2011**, 50, 179–207
- Deeley R. *Get al.* Overexpression of multidrug resistant human lung cancer cell line. *Science* 258, **1992**, 1650–1654
- Dean M. The genetics of ATP-binding cassette transporters. *Methods Enzymol.* **2005**, 400:409–29
- Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., and Gottesman, M. M. (2006) Targeting multidrug resistance in cancer. *Nat. Rev. Drug Discov.* 5, 219 – 234.
- Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity *Rev.* **2013**, 32:211–27
- Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al.. A multidrug resistance transporter from human *Proc. Natl. Acad. Sci. USA* , **1998**, 95:15665–70
- Sharom FJ.. The P-glycoprotein multidrug transporter structure. *Essays Biochem.* **2011**, 50:161–78
- Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). *Curr. Drug Metab.* **2010**, 11:60317
- Keppler D. Multidrug resistance proteins (MRPs, ABCs): importance for pathophysiology and drug therapy. *Handb. Exp. Pharmacol.* **2011**, 201:299–323
- Yang Y, Mo W, Zhang JT. Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCG1. *Biochemistry* **2010**, 49:10854–61
- Brozik Aet al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters. *Expert Opin. Drug Metab. Toxicol.* **2011**, 7:623–42.



13. Knauer MJ *et al.* Human skeletal muscle drug transporters determine local exposure and toxicity of statins. *Circ. Res.* **2010**,106:297–306.
14. Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, *et al.* ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. *Cell Biol. Int.* **2012**, 36:79–86.
15. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, *et al.* Association of high level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. *J. Clin.Oncol.* **2006**, 24:1546–53.

